Back to Search
Start Over
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
- Source :
- Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, CLINICAL INFECTIOUS DISEASES, Clinical Infectious Diseases, 62(5), 655-663. Oxford University Press, Clinical infectious diseases, 62(5), 655-663. Oxford University Press, Clinical Infectious Diseases, Clin.Infect.Dis., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname, Hofstra, L M, Sauvageot, N, Albert, J, Alexiev, I, Garcia, F, Struck, D, Van de Vijver, D A M C, Åsjö, B, Beshkov, D, Coughlan, S, Descamps, D, Griskevicius, A, Hamouda, O, Horban, A, Van Kasteren, M, Kolupajeva, T, Kostrikis, L G, Liitsola, K, Linka, M, Mor, O, Nielsen, C, Otelea, D, Paraskevis, D, Paredes, R, Poljak, M, Puchhammer-Stöckl, E, Sönnerborg, A, Staneková, D, Stanojevic, M, Van Laethem, K, Zazzi, M, Zidovec Lepej, S, Boucher, C A B, Schmit, J-C, Wensing, A M J & SPREAD Program 2016, ' Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe ', Clinical Infectious Diseases, vol. 62, no. 5, pp. 655-663 . https://doi.org/10.1093/cid/civ963, Clinical Infectious Diseases, 62(5), 655. Oxford University Press
- Publication Year :
- 2016
-
Abstract
- Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.<br />Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)–infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%–9.5%) in 2008–2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
- Subjects :
- Male
Human immunodeficiency virus 1
Etravirine
RNA directed DNA polymerase inhibitor
darunavir
HIV Infections
Settore MED/42 - Igiene Generale E Applicata
Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]
Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]
Salud pública
genetics
Inhibidores de proteasas
Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]
atazanavir
media_common
transmission
Geographicals::Geographic Locations::Europe [Medical Subject Headings]
3. Good health
microbial sensitivity test
priority journal
Europe
HIV-1
antiretroviral therapy
drug resistance
HIV/AIDS
lamivudine
Reverse Transcriptase Inhibitors/pharmacology
anti human immunodeficiency virus agent
Drug
Microbiology (medical)
medicine.medical_specialty
antiviral susceptibility
Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]
media_common.quotation_subject
030106 microbiology
HIV Infections/drug therapy
Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]
Microbial Sensitivity Tests
RILPIVIRINE
Article
EFAVIRENZ
03 medical and health sciences
transmitted drug resistance
SDG 3 - Good Health and Well-being
Humans
Transmission
human
Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]
REVERSE-TRANSCRIPTASE INHIBITORS
Rilpivirina
INTEGRASE
MUTATIONS
abacavir
major clinical study
Virology
Infecciones por VIH
Regimen
Antiretroviral therapy
Drug resistance
Medicine (all)
Infectious Diseases
chemistry
Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]
Mutation
0301 basic medicine
nevirapine
Communicable diseases
Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]
chemistry.chemical_compound
antiviral therapy
INFECTION
Medicine and Health Sciences
Prevalence
Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]
Viral
Non-U.S. Gov't
Reverse-transcriptase inhibitor
antiretrovirus agent
Research Support, Non-U.S. Gov't
Human immunodeficiency virus infected patient
Middle Aged
virology
PREVALENCE
Encuestas y Cuestionarios
ANTIRETROVIRAL TREATMENT
HIV-1/drug effects
HIV Protease Inhibitors/pharmacology
Rilpivirine
Reverse Transcriptase Inhibitors
Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]
Female
HIV drug resistance
medicine.drug
Adult
Human immunodeficiency virus proteinase inhibitor
Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]
Efavirenz
Anti-HIV Agents
Research Support
Resistencia a medicamentos
Settore MED/17 - MALATTIE INFETTIVE
antiviral resistance
Internal medicine
Anti-HIV Agents/pharmacology
Drug Resistance, Viral
Journal Article
medicine
Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]
abacavir plus lamivudine
Europa (Continente)
HIV Protease Inhibitors
emtricitabine
nonhuman
Intervalos de confianza
Mutación
business.industry
HIV
prediction
Inhibidores de la transcriptasa inversa
Human immunodeficiency virus 1 infection
tenofovir
INDIVIDUALS
Drug Resistance, Viral/genetics
Benzoxazinas
ETRAVIRINE
drug effects
3121 General medicine, internal medicine and other clinical medicine
Prevalencia
business
Subjects
Details
- Language :
- English
- ISSN :
- 10584838 and 15376591
- Database :
- OpenAIRE
- Journal :
- Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, CLINICAL INFECTIOUS DISEASES, Clinical Infectious Diseases, 62(5), 655-663. Oxford University Press, Clinical infectious diseases, 62(5), 655-663. Oxford University Press, Clinical Infectious Diseases, Clin.Infect.Dis., Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA, instname, Hofstra, L M, Sauvageot, N, Albert, J, Alexiev, I, Garcia, F, Struck, D, Van de Vijver, D A M C, Åsjö, B, Beshkov, D, Coughlan, S, Descamps, D, Griskevicius, A, Hamouda, O, Horban, A, Van Kasteren, M, Kolupajeva, T, Kostrikis, L G, Liitsola, K, Linka, M, Mor, O, Nielsen, C, Otelea, D, Paraskevis, D, Paredes, R, Poljak, M, Puchhammer-Stöckl, E, Sönnerborg, A, Staneková, D, Stanojevic, M, Van Laethem, K, Zazzi, M, Zidovec Lepej, S, Boucher, C A B, Schmit, J-C, Wensing, A M J & SPREAD Program 2016, ' Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe ', Clinical Infectious Diseases, vol. 62, no. 5, pp. 655-663 . https://doi.org/10.1093/cid/civ963, Clinical Infectious Diseases, 62(5), 655. Oxford University Press
- Accession number :
- edsair.doi.dedup.....41b36da0d354012c11ec6a9ed8516493